Why Bioavailability Cannot Be Ranked by Route Alone

Peptide bioavailability cannot be ranked by route alone because bioavailability is measured for a specific peptide, molecular form, formulation, administered quantity, route, reference condition, population, sampling schedule, and analytical method. Oral, buccal, sublingual, intranasal, subcutaneous, intramuscular, and intravenous administration create different experimental environments, but the route label does not determine the final exposure value independently of the peptide and formulation being studied.

This distinction is central to peptide bioavailability research. Route comparisons are useful when the experimental conditions are sufficiently controlled, but placing routes into a universal highest-to-lowest hierarchy removes the product-specific information required to interpret bioavailability.

This article is provided for general educational purposes and explains formulation, delivery, and research concepts associated with peptide bioavailability research. It does not establish the regulatory status of any specific InStrips product or determine whether a particular product is appropriate for any person.

A bioavailability percentage reported for one peptide formulation should not be presented as the bioavailability of an entire administration route or used to predict how an unrelated peptide would behave.

Bioavailability Is Not a Fixed Property of a Route

Bioavailability describes measured systemic exposure relative to a defined reference under specified conditions.

It depends on variables including:

• peptide identity
• molecular form
• formulation
• administered quantity
• delivered quantity
• route
• reference condition
• study design

Route is therefore one contributor to the result rather than the complete explanation.

Peptides Are Chemically Diverse

Peptides differ in sequence, size, charge, shape, stability, and chemical modification.

These differences may affect:

• enzyme sensitivity
• mucus diffusion
• epithelial transport
• tissue binding
• lymphatic transport
• renal clearance
• aggregation

A route that produces one exposure profile for one peptide may produce a different profile for another peptide.

Molecular Size Changes Route-Specific Behavior

Molecular size can influence diffusion, transport pathways, tissue movement, and clearance.

For example, size may affect:

• epithelial permeability
• lymphatic uptake
• renal filtration
• mucus diffusion
• distribution from an injection site

A route cannot therefore be assigned one bioavailability value across peptides of different sizes.

Peptide Charge Matters

Charge can affect solubility, membrane interaction, mucus binding, protein association, and formulation behavior.

Charge itself may change with:

• pH
• counterion form
• chemical modification
• local formulation environment

Two peptides delivered through the same route can therefore encounter different transport limitations.

Peptide Stability Matters

Peptides can undergo chemical or enzymatic change before or after systemic entry.

Potential processes include:

• proteolytic cleavage
• oxidation
• deamidation
• aggregation
• surface adsorption

The relevant degradation pathways differ among gastrointestinal, mucosal, nasal, tissue, and systemic environments.

Formulation Can Change Bioavailability Substantially

The same peptide sequence can be incorporated into different formulations.

Formulation changes may involve:

• buffers
• lipids
• polymers
• surfactants
• coatings
• permeation-related components
• enzyme-related components
• controlled-release materials

A route comparison that ignores formulation differences can attribute a formulation effect incorrectly to route.

Oral Formulations Are Not One Category

Oral peptide formulations can use very different technologies.

Examples include:

• enteric-coated dosage forms
• lipid systems
• nanoparticles
• permeation-related formulations
• enzyme-related formulations
• ingestible devices

Two oral peptide formulations may therefore produce different exposure even though their route label is identical.

Intranasal Formulations Are Also Variable

Intranasal research may use liquids, powders, gels, particles, mucoadhesive materials, or other systems.

Results can depend on:

• device type
• droplet or particle size
• deposition
• formulation volume
• mucociliary clearance
• mucus interaction

There is no single intranasal bioavailability value for all peptide formulations.

Buccal and Sublingual Formulations Differ

Oral-mucosal studies may use films, patches, tablets, sprays, gels, or solutions.

Formulation characteristics influence:

• residence time
• peptide release
• salivary dilution
• swallowed fraction
• mucosal transport

Buccal and sublingual routes also involve different tissue regions and should not be pooled automatically.

Subcutaneous Formulations Differ

Subcutaneous formulations can vary in concentration, viscosity, physical state, injection volume, and release characteristics.

These differences may change:

• local dispersion
• absorption rate
• lymphatic contribution
• Cmax
• Tmax
• AUC

A subcutaneous route label does not describe these formulation variables.

Intramuscular Formulations Differ

Intramuscular formulations may also range from rapidly dispersed solutions to materials with prolonged local retention.

Exposure can be affected by:

• muscle site
• vascularity
• volume
• viscosity
• injection depth
• formulation release

One intramuscular study cannot define the route as a whole.

Intravenous Bioavailability Has a Specific Meaning

Intravenous administration is commonly used as a reference for absolute bioavailability because the formulation enters systemic circulation directly under the protocol.

This does not mean intravenous research answers every route question.

It does not describe:

• mucosal transport
• gastrointestinal release
• injection-site absorption
• formulation residence
• local tissue release

The route provides a reference condition for specific pharmacokinetic calculations.

Absolute and Relative Bioavailability Should Not Be Mixed

An absolute bioavailability percentage and relative bioavailability percentage answer different questions.

Absolute calculations generally use an intravenous reference.

Relative calculations may compare:

• two formulations
• two non-intravenous routes
• two administration conditions
• fed and fasted states

Percentages calculated using different references cannot be ranked as though they measure the same quantity.

The Reference Formulation Matters

Even when intravenous administration is used as a reference, the reference formulation should be identified.

Relevant variables may include:

• peptide form
• concentration
• buffer
• purity
• delivered quantity
• analytical recovery

A poorly matched reference can complicate interpretation of the calculated percentage.

Administered Quantity Matters

Exposure comparisons may use different peptide quantities across routes.

Researchers may normalize AUC for the administered quantity when appropriate.

This requires confidence in:

• formulation content
• device delivery
• dose recovery
• route-specific losses

Nominal quantities should not be assumed to equal delivered quantities.

Nonlinear Pharmacokinetics Can Complicate Normalization

Simple quantity normalization assumes that exposure changes predictably with administered quantity.

That relationship may be altered by:

• saturable transport
• nonlinear clearance
• limited solubility
• aggregation
• formulation changes at higher concentrations

Bioavailability comparisons should therefore consider whether dose proportionality has been evaluated.

Cmax Cannot Rank Routes

Cmax reflects the highest concentration captured by the sampling schedule.

A higher Cmax may result from:

• faster absorption
• rapid formulation release
• different sampling timing
• lower distribution volume
• slower early clearance

It does not by itself establish greater total exposure.

Tmax Cannot Rank Routes

Tmax describes timing rather than exposure magnitude.

A shorter Tmax indicates that the observed concentration maximum occurred earlier.

It does not establish:

• higher AUC
• higher absolute bioavailability
• lower variability
• equivalence between formulations

AUC Is More Comprehensive but Still Study-Specific

AUC integrates systemic concentration over a defined interval, making it central to many bioavailability calculations.

AUC still depends on:

• sampling schedule
• study duration
• analytical sensitivity
• extrapolation
• missing samples
• peptide specificity of the assay

An AUC from one study should not be ranked against an unrelated AUC without evaluating these variables.

Analytical Assays Can Produce Different Exposure Estimates

Peptide studies may use immunoassays, chromatography, mass spectrometry, or combinations of methods.

Assays can differ in their ability to distinguish:

• intact peptide
• fragments
• metabolites
• endogenous peptide
• bound peptide

A larger measured concentration may reflect assay recognition as well as pharmacokinetic behavior.

Sampling Schedules Can Create Apparent Route Differences

A rapidly appearing peptide concentration can be underestimated if early samples are too widely spaced.

A slowly released formulation can be underestimated if sampling ends too early.

Route comparisons therefore require schedules capable of characterizing:

• initial appearance
• Cmax
• Tmax
• terminal decline
• late release

Study Populations Matter

Peptide exposure can vary with physiological characteristics.

Relevant factors may include:

• age
• body size
• body composition
• renal function
• hepatic function
• concurrent substances
• local tissue characteristics

A route result in one study population cannot automatically be transferred to another population.

Animal and Human Route Rankings Cannot Be Combined Directly

Animal species can differ from humans in:

• gastrointestinal anatomy
• nasal anatomy
• tissue vascularity
• enzyme activity
• clearance
• lymphatic transport

A route comparison in an animal model should therefore remain identified as animal evidence.

Within-Study Comparisons Are More Informative Than Cross-Study Rankings

A controlled study comparing two routes can hold several variables relatively constant.

It may use:

• the same peptide batch
• the same analytical method
• the same population
• matched sampling
• predefined calculations

Cross-study rankings usually introduce many additional differences that cannot be separated easily.

Cross-Study Tables Can Be Misleading

A table listing bioavailability percentages from unrelated studies may appear precise while comparing different:

• peptides
• routes
• formulations
• references
• species
• assays
• study designs

The percentages should not be interpreted as a route leaderboard unless the studies are genuinely comparable.

Variability Is as Important as the Average

Two formulations may have similar average exposure while differing substantially in individual variability.

Researchers may report:

• standard deviation
• coefficient of variation
• range
• individual concentration-time profiles
• within-subject differences

A ranking based only on averages removes this information.

Route Ranking Can Hide Failure at Different Stages

Low measured exposure can result from different processes depending on route.

Examples include:

• incomplete oral release
• gastrointestinal degradation
• limited mucosal transport
• nasal clearance
• swallowed nasal material
• local injection-site retention
• analytical loss

Understanding where loss occurs is often more informative than assigning the route a single rank.

Bioavailability Does Not Rank Every Other Research Property

Bioavailability is a pharmacokinetic measurement.

It should not be used automatically to rank routes according to unrelated features such as:

• stability before administration
• manufacturing complexity
• formulation variability
• local tissue findings
• analytical complexity

Each research property requires its own measurements.

Greater Exposure Does Not Establish a Broader Outcome

A route producing greater measured systemic exposure in one experiment has established an exposure difference under those conditions.

That observation does not independently establish:

• another biological outcome
• results for another peptide
• results at another quantity
• equivalence among formulations
• a general route hierarchy

Peptide Pharmacokinetic Literature Supports Product-Specific Interpretation

A review available through the National Library of Medicine describes how peptide pharmacokinetics can vary with molecular properties, route of administration, renal and hepatic function, and other intrinsic and extrinsic factors.

This framework supports evaluating bioavailability as a peptide-specific and study-specific measurement rather than assigning a fixed value to an administration route.

Direct SC-vs-IM Comparisons Illustrate the Principle

Even two parenteral routes that both avoid gastrointestinal barriers create different tissue environments and absorption processes.

The variables involved are examined in How Subcutaneous and Intramuscular Peptide Exposure Is Compared.

What Route Comparisons Can Establish

A properly controlled comparison may establish that under defined conditions:

• one route produces a different Cmax
• one route produces a different Tmax
• total measured exposure differs
• absolute or relative bioavailability differs
• variability differs
• formulation and route interact with exposure

What Route Comparisons Cannot Establish

A route comparison does not automatically establish:

• a universal hierarchy of administration routes
• the bioavailability of another peptide
• the bioavailability of another formulation
• results in another species or population
• equivalence among delivery systems
• results at another administered quantity
• performance outside the tested conditions

Final Perspective

Peptide bioavailability cannot be ranked by route alone because route is only one element in a complex peptide-formulation-study system.

Molecular identity, size, charge, stability, formulation technology, administered and delivered quantities, reference condition, anatomy, sampling schedule, analytical specificity, population, and variability all contribute to the measured result.

Accurate interpretation compares defined peptide-formulation-route combinations under sufficiently comparable conditions rather than turning oral, mucosal, nasal, subcutaneous, intramuscular, and intravenous administration into a universal highest-to-lowest bioavailability ranking.